Since July, a number of well-known pharmaceutical companies have been acquired.

"Pharmaceutical Network Industry Dynamics" 2020 is an important year for the implementation of the medical reform policy, with the expansion of volume procurement, the third batch of band procurement is about to be implemented; Every pharmaceutical company is deeply affected; big public companies, or small pharmaceutical companies, are trying to make changes to cope with the rush of policies.
in this context, the merger and reorganization of the pharmaceutical industry has gradually become an important means to support the real economic development of the market, a number of pharmaceutical enterprises have also begun to achieve joint through mergers and reorganizations, has promoted the high-quality development of the pharmaceutical industry.
National Medicine unanimously transferred to 100% of Dayuan's 100% equity on July 21, The State Pharmaceutical Industry unanimously issued a public announcement that it intends to publicly delist the transfer of 100% of Dafang Yuan Pharmaceutical Group Co., Ltd., the public listing transfer floor price of 1.86 billion yuan.
according to the announcement, Cheng Dafangyuan is a regional large-scale pharmaceutical circulation enterprise that brings together the pharmaceutical retail chain and logistics and distribution, and has 1507 stores in 19 cities in 5 provinces and 19 cities, covering Liaoning, Jilin, Inner Mongolia, Shandong and Hebei.
Hanfang Pharmaceuticals, Dechangxiang Pharmaceuticals was also acquired July 20, Guizhou Sanli Pharmaceuticals announced that it intends to increase capital to Guizhou Hanfang Pharmaceutical Co., Ltd., Guiyang Dechangxiang Pharmaceutical Co., Ltd. through cash, to acquire hanfang Pharmaceuticals, Dechangxiang Pharmaceuticals not more than 51% of the equity.
it is understood that Sanli Pharmaceuticals intends to pay a deposit of RMB 100 million to the asset control party, according to the agreement between the two parties, in addition to a deal price can not be agreed between the two sides, such as the company's unilateral reasons to terminate the transaction, the asset control party has the right not to refund the transaction deposit paid by the listed company.
Haizheng Pharmaceuticals to buy a 49% stake in Hanyu Pharmaceuticals on July 20, Haizheng Pharmaceuticals announced that it will issue shares, convertible corporate bonds and pay cash to HPPC Holding SARL to buy 49% of Hanyu Pharmaceuticalcos Co., Ltd. (hereinafter referred to as "Hanyu Pharmaceuticals") 49% stake, and raise supporting funds.
the deal is completed, Hanyu Pharmaceuticals will be taken over by its parent company, Haizheng Pharmaceuticals, with a 100% stake.
HPPC, which was previously a major shareholder in Hanyu Pharmaceuticals, will also become a shareholder in Haizheng Pharmaceuticals through a restructuring deal that indirectly takes a stake in Haizheng Pharmaceuticals, with a stake of more than 5%.
Merya to buy friends health shares on July 10, Hubei American Arya Co., Ltd. announced that it intends to issue shares and pay cash to buy the shares of Gansu Zhongyou Health Pharmaceutical Co., Ltd., while the non-public issue of shares to raise supporting funds.
it is understood that the company's existing main business for clothing, clothing and textile research and development, design, manufacturing and sales.
and friends health, is mainly engaged in drug chain retail business, in Gansu, Shaanxi, Qinghai and other ten provinces, autonomous regions, municipalities directly under the Central Government has more than 3000 chain pharmacies, is a large-scale pharmaceutical chain operating enterprises.
is understood that the purchase of health equity of the United States, mainly due to the textile and garment industry competition is more intense, listed companies existing business growth pressure is greater.
in order to protect the interests of shareholders and the company's future sustained and healthy development, it decided to buy friends health equity, for the company to inject sustained profitability of the pharmaceutical retail industry high-quality assets.
Guangshengtang's acquisition of 5% of ZTE Pharmaceuticals, A.S. Limited, announced on July 1 that the company and the holding subsidiary ZTE Pharmaceuticals minority shareholders Pan Lifei and Pan Liqiang signed the Equity Transfer Agreement, each with a price of 5.25 million yuan to buy 5% of ZTE Pharmaceuticals, each holding 5% of the shares.
the deal is completed, the company will take a 92.5% stake in ZTE Pharmaceuticals.
is understood that Guangshengtang was established in June 2001, after landing on the Shenzhen Stock Exchange listed in April 2015, at present, it has formed a nucleoside (auxo) anti-hepatitis B virus drugs as the core, covering hepatitis B, hepatitis C, fatty liver, liver cancer, liver protection and other liver health product line layout.
it is worth noting that in recent years, in addition to Guangshengtang company holding more than 5% of shareholders frequently reduce their holdings, last year, in fact, the controller and chairman also due to personal financial arrangements needs, in order to centralize bidding and bulk trading to reduce the total number of shares of the company not more than 810,000 shares (0.58% of the company's total share capital).
concluded that since 2020, mergers and acquisitions between pharmaceutical companies have been frequent, and these are only some of the acquisitions in July.
but looking at these cases reveals that pharmaceutical companies are mainly strengthening their strengths through acquisitions and "slimming down" by selling non-core assets.
in general, this means that the industry is moving towards greater concentration.
the future, with the deepening of medical reform, consistency evaluation, volume procurement, DRG and other policies, the industry access threshold increased, small and medium-sized enterprises by large enterprises are expected to be more frequent acquisitions.
.